[ad_1] WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved […]
[ad_1] WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ — Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy […]
[ad_1] WALTHAM, Mass., Nov. 1, 2024 /PRNewswire/ — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved […]
